孕产妇接受β-阻断剂治疗对胎儿心率平均值的影响
Sarah Hautier1, Thi Minh Thu Nguyen2, Arane Kim3
1Assistance Publique-Hôpitaux de Paris, Service de Gynécologie-Obstétrique, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin-Bicetre, France (Hautier and Luton).
AJOG global reports
|January 6, 2025
概括
在怀孕期间使用β-阻断剂并没有显著影响胎儿心率. 由于子宫内生长限制等潜在风险,对服用β-阻断剂的孕妇进行密切监测仍然至关重要.
科学领域:
- 产科和妇科 产科和妇科
- 心脏病学 心脏病学
- 围产儿医学 围产儿医学
背景情况:
- 贝塔抑制剂药物有时在怀孕期间用于治疗母亲的慢性疾病.
- 人们担心母亲使用β-阻断剂对胎儿发育和福祉的潜在影响.
研究的目的:
- 为了评估母体β抑制剂治疗对胎儿心率平均值的影响.
- 为了比较使用β阻塞剂的孕妇与未经治疗的对照组的胎儿心率.
主要方法:
- 对90名孕妇进行了回顾性病例对照研究 (45名接受β-阻断剂治疗,45名未接受治疗).
- 患者在分娩时 (在24周后) 根据年龄,平价和妊娠年龄进行了匹配.
- 胎儿和母亲的心率记录在分娩当天;怀孕结果是次要终点.
主要成果:
- 在β阻塞剂组和对照组之间没有观察到胎儿心率平均值的统计学上显著差异.
- 贝塔阻断剂组中的87%的胎儿和对照组中的93%的胎儿心率在每分钟110-150次之间 (P=.71).
- 比索普罗罗罗尔是治疗组中最常用的β-阻断剂.
结论:
- 孕产妇的β-阻断剂治疗似乎没有显著改变胎儿的心率.
- 持续警和临床管理对于接受β抑制剂的孕妇至关重要,考虑到其他潜在风险,如子宫内生长限制.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
378
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
378
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
473
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
473
Heart Failure Drugs: β-Blockers
257
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
257
Antihypertensive Drugs: Types of β-Blockers
498
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
498
Antihypertensive Drugs: Action of β1 Blockers
258
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
258
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
636
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
636


